Resveratrol inhibits firefly luciferase |
| |
Authors: | Bakhtiarova Adel Taslimi Paul Elliman Stephen J Kosinski Penelope A Hubbard Brian Kavana Michael Kemp Daniel M |
| |
Affiliation: | Diabetes and Metabolism Disease Area, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139, USA. |
| |
Abstract: | The potential therapeutic value of resveratrol in age-related disease settings including cancer, diabetes, and Alzheimer's has emerged from a rapidly growing body of experimental evidence. Protection from oxidative stress appears to be a common feature of resveratrol that may be mediated through SirT1, though more specific molecular mechanisms by which resveratrol mediates its effects remain unclear. This has prompted an upsurge in cell-based mechanistic studies, often incorporating reporter assays for pathway elucidation in response to resveratrol treatment. Here, we report that resveratrol potently inhibits firefly luciferase with a K(i) value of 2microM, and caution that this confounding element may lead to compromised data interpretation. |
| |
Keywords: | Resveratrol Firefly luciferase SirT1 Therapeutic Drug Cancer Neurodegeneration |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|